Peer-reviewedCC BY-NC-ND 4.0eClinicalMedicine
Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer
Related
- Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
- BCAR4, BCAR3 and EGFR Display Different Degrees of Cross-Resistance to Endocrine Mono- and Combination Therapies in Hormone Receptor Positive, HER2 Negative Breast Cancer
- Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
- Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer
- Primary Endocrine Therapy vs Upfront Surgery for Older Women With Estrogen Receptor–Positive Breast Cancer
BibTeX
@article{glaviano2026targeting,
title = {{Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer}},
author = {Antonino Glaviano and Rachel O. Abelman and Andreas Varkaris and Samika Varma and Kelly E. McCann and Alan Prem Kumar and Patrizia Diana and Robertus A.M. de Bruin and Dejan Juric and Neil Vasan and Seth A. Wander},
journal = {eClinicalMedicine},
year = {2026},
month = nov,
doi = {10.1016/j.eclinm.2026.104320},
url = {https://linkinghub.elsevier.com/retrieve/pii/S2589537026005730},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer
AU - Antonino Glaviano
AU - Rachel O. Abelman
AU - Andreas Varkaris
AU - Samika Varma
AU - Kelly E. McCann
AU - Alan Prem Kumar
AU - Patrizia Diana
AU - Robertus A.M. de Bruin
AU - Dejan Juric
AU - Neil Vasan
AU - Seth A. Wander
PY - 2026
DA - 2026/11/01
JO - eClinicalMedicine
DO - 10.1016/j.eclinm.2026.104320
UR - https://linkinghub.elsevier.com/retrieve/pii/S2589537026005730
SN - 2589-5370
ER -